Skip to main content
. Author manuscript; available in PMC: 2013 Nov 19.
Published in final edited form as: Blood. 2011 Aug 5;118(13):10.1182/blood-2010-09-311076. doi: 10.1182/blood-2010-09-311076

Figure 3. Interaction between Siglec-9 and VAP-1 involves both enzyme activity dependent and independent mechanisms.

Figure 3

(A) Binding of CFSE labelled CHO-Siglec-9 transfectants to CHO cells expressing wild type VAP-1 (CHO-VAP-1), or the enzymatically inactive VAP-1 (CHO-VAP-1Y471F) and to mock transfected controls (CHO-mock). Binding is expressed as relative binding (mean ± SD, n = 5). *P < 0.05; **P < 0,01; ***P < 0.001. (B) Fluorescence microscopy images of the binding are shown as indicated. (C) Surface plasmon resonance analyses of the cyclic wild type Siglec-9-like peptide at different concentrations (0-400 μM). (D) An example of surface plasmon resonance analyses with the wild type and the mutated Siglec-9-like peptides. Three experiments were performed with comparable results. Arg 1 = Arg 284 and Arg 2 = Arg 290, Pept = wild type peptide.